Generic Name and Formulations:
Norelgestromin 150mcg/day, ethinyl estradiol 35mcg/day; transdermal patch.
Indications for XULANE:
Limitations Of use:
May be less effective in patients ≥90kg (198lbs).
Apply to abdomen, buttock, upper outer arm, or back; with each new patch, rotate application site (may use same anatomic area). Apply 1 patch once weekly for 3 weeks, then 1 patch-free week; repeat.
Premenarchal: not applicable.
High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or PE, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Undiagnosed abnormal uterine bleeding. Breast or other estrogen- or progestin-sensitive neoplasms. Hepatic disease or tumors. Pregnancy. Concomitant ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.
Cardiovascular risk associated with smoking. Risk of venous thromboembolism. Pharmacokinetic profile of ethinyl estradiol.
Discontinue if thrombotic event, unexplained visual changes, or jaundice occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Higher estrogen exposure than oral contraceptives (may increase adverse events risk). Gallbladder disease. Uncontrolled dyslipidemia. Hypertriglyceridemia; increased risk of pancreatitis. Diabetes. Obesity. Depression. Hereditary angioedema. Cholasma gravidarum. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Monitor blood pressure. Do regular complete physical exams. Use barrier contraception with Sunday starts or postpartum starts (see full labeling). Nursing mothers: not recommended.
Progestin + estrogen.
See Contraindications. ALT elevations with HCV regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir; discontinue Xulane prior to starting HCV regimen and restart 2wks after completion. Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's Wort, barbiturates, bosentan, carbamazepine, felbamate, oxcarbazepine, phenytoin, topiramate), possibly others. May antagonize lamotrigine; consider dosage adjustment. May be affected by HIV protease inhibitors, NNRTIs. May be potentiated by acetaminophen, ascorbic acid, atorvastatin, rosuvastatin, and CYP3A4 inhibitors (eg, itraconazole, ketoconazole, voriconazole, fluconazole, grapefruit juice). May potentiate cyclosporine, prednisolone, theophylline, tizanidine, voriconazole. May antagonize acetaminophen, clofibric acid, morphine, salicyclic acid, temazepam. May affect measurement of clotting factors, thyroid binding globulin, sex hormone binding globulin, lipds, glucose, other serum binding proteins.
Breast symptoms, nausea, vomiting, headache, application site disorder, abdominal pain, dysmenorrhea, vaginal bleeding, menstrual disorders, mood, affect, and anxiety disorders; hypertension, amenorrhea, oligomenorrhea, transient delay of ovulation after discontinuation, edema, intolerance to contact lens, possible venous thromboembolism; others (see full labeling).
Hepatic. >97% protein bound.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|